Blocking the A2B adenosine receptor alleviates myocardial damage by inhibiting spleen-derived MDSC mobilisation after acute myocardial infarction

Zongying Yu; Yang Ling; Qiancheng Xu; Yuhan Cao; Shengxing Tang; Cong Fu

doi:10.1080/07853890.2022.2084153

. 2022 Jun 8;54(1):1616–1626. doi: 10.1080/07853890.2022.2084153

Blocking the A_2B adenosine receptor alleviates myocardial damage by inhibiting spleen-derived MDSC mobilisation after acute myocardial infarction

Zongying Yu ^a,^b, Yang Ling ^a, Qiancheng Xu ^c, Yuhan Cao ^d,^e, Shengxing Tang ^a,^✉, Cong Fu ^a,^b,^e,^✉

PMCID: PMC9186371 PMID: 35675334

Abstract

Background

Myeloid-derived suppressor cell (MDSC) mobilisation is an important immune event in acute myocardial infarction (AMI). The A_2B adenosine receptor (A_2BAR) plays key role in regulating MDSC function, but its specific involvement in MDSC mobilisation in AMI remains unclear.

Methods

In AMI patients, the circulating MDSC ratio and A_2BAR mRNA expression were measured. A mouse AMI model was established by left anterior descending coronary artery (LADCA) ligation. MDSCs were analysed by FACS and immunofluorescence staining (of heart tissue). A_2BAR mRNA expression was assessed by qRT-PCR. Myocardial injury was detected by HE staining. Myocardial cell apoptosis was analysed by immunohistochemistry. Cardiac systolic function was evaluated by transthoracic echocardiography.

Results

In AMI patients, the circulating MDSC ratio was increased and positively correlated with A_2BAR mRNA expression (r = 0.86, p < 0.01). In AMI model mice, the percentage of MDSCs was increased in the circulation and infarcted heart and decreased in the spleen. MRS-1754-mediated A_2BAR inhibition decreased the MDSC ratio in the circulation and infarcted heart and prevented the decrease in MDSC number in the spleens of mice with AMI. A_2BAR blockade inhibited myocardial cell apoptosis, alleviated myocardial inflammatory injury, and improved myocardial systolic function in the AMI mouse model. Similar results were found in mice after splenectomy. Additionally, spleen-derived MDSC injection increased the MDSC ratio in the infarcted heart, increased myocardial cell apoptosis, aggravated myocardial injury, and decreased cardiac systolic function in mice with AMI.

Conclusion

Blocking A_2BAR alleviates myocardial damage and improves myocardial systolic function through inhibition of spleen-derived MDSC mobilisation after AMI.

Key Messages

Spleen-derived MDSC mobilisation aggravates myocardial inflammatory injury within 24 h of AMI.
A_2BAR promotes spleen-derived MDSC mobilisation within 24 h of AMI.
Blocking A_2BAR improves myocardial systolic function through inhibition of spleen-derived MDSC mobilisation.

Keywords: Acute myocardial infarction, MDSCs, A_2B adenosine receptor, spleen

1. Introduction

Acute myocardial infarction (AMI) is a cardiac emergency involving myocardial necrosis caused by unstable coronary artery ischaemic syndrome, and remains a leading cause of death and disability worldwide [1–3]. Recent studies on AMI have shown that a persistent proinflammatory reaction plays a vital role in determining the myocardial infarction (MI) size and subsequent left ventricle remodelling [4–6]. Undoubtedly, regulating the inflammatory response to AMI is a potential therapeutic strategy for limiting the MI size and improving outcomes following AMI [5].

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cell progenitors and precursors and are generated during biological stress, including tissue damage and inflammation [7–9]. Mouse MDSCs are CD11b⁺ and Gr-1⁺, while human MDSCs are mostly CD11b⁺ and CD14^- [9–11]. These cells were first described more than 20 years ago in patients with cancer [12], and increasing evidence indicates that MDSCs are universal regulators of immune function in various heart diseases, such as aging-related cardiac fibrosis [13], acute coxsackievirus B3-induced myocarditis [14], and sepsis-induced myocardial injury [15]. A recent study suggested that enhanced infiltration of MDSCs by advanced glycation end-products contributes to aggravation of myocardial injury in mice with AMI [16]. Our previous study found that MDSCs participate in all pathogenic processes of acute coronary syndrome by gradually differentiating into foam-like and neutrophil-like cells [17]. Therefore, improving our understanding of MDSC mobilisation may provide clues for improving therapeutic strategies for AMI.

A_2B adenosine receptor (A_2BAR), a member of the adenosine receptor family, plays critical roles in tumours and cardiovascular diseases through its proangiogenic effects [18–21]. Blockade of A_2BAR attenuates cardiac remodelling, ameliorates left ventricular dysfunction, and improves cardiac outcomes after AMI in animal models [22–24]. In many tumour models, A_2BAR blockade or knockout reduces tumour-associated MDSC accumulation and leads to a significant delay in tumour growth [25–29]. However, whether A_2BAR can regulate MDSC mobilisation in AMI remains unclear.

Therefore, this study was designed to confirm whether MDSCs infiltrate myocardial tissue and further lead to myocardial injury during AMI. Furthermore, we aimed to investigate the origin of MDSCs. Moreover, a preliminary mechanism of and possible strategies for intervening in MDSC mobilisation are discussed.

2. Methods

2.1. AMI patients

Blood samples were collected from the peripheral veins of 10 AMI patients who underwent emergency coronary angiography (CAG) and were hospitalised in the cardiology ward of Yi Ji Shan Hospital affiliated to Wan Nan Medical College. Ten age- and sex-matched patients without coronary artery disease, as confirmed by CAG, were included as controls. There was no significant difference in the basic data between the 2 groups (Supplementary Table 1). All participants agreed to participate in the study and provided written informed consent. The study protocol was approved by the Ethics Committee of Yi Ji Shan Hospital.

2.2. Mice grouping and AMI model

Male C57BL6 mice (age: 6–8 weeks, weight: 20–25 g) were used according to the guidelines of the Animal Ethics Committee of Yi Ji Shan Hospital affiliated to Wan Nan Medical College. Mice were randomly divided into 6 groups. Control group (n = 5): mice did not receive any operations. Sham group (n = 5): mice underwent control operation without coronary artery ligation. AMI group (n = 10): mice underwent LADCA ligation. A_2BAR blocking group (n = 10): mice received A_2BAR antagonist MRS1784 (1 mg/kg) [30] intraperitoneally injection before LAD ligation. Splenectomy group (n = 10): mice underwent splenectomy before LAD ligation. MDSCs injection group (n = 10): the splenectomy mice immediately received isolated MDSCs (2 × 10^5/ml) injection via the medial canthus vein before LADCA ligated.

AMI was induced by ligation of the left anterior descending artery (LADCA) [31]. Briefly, the mice were anaesthetised by intraperitoneal injection of sodium pentobarbital (35 mg/kg) (Sigma-Aldrich, USA) and intubated. Then, the LADCA was ligated proximally with 7-0 silk sutures via a left thoracotomy incision. Paleness of the anterior wall of the left ventricle indicated successful induction of AMI. All mice were housed in an SPF animal facility with unrestricted access to food and water.

Splenectomy was performed as previous described [32]. A skin incision (approximately 0.5 cm) is made in vertical midline abdomen of adequate anaesthetised mice. After ligation of the relevant vessels, spleen was removed to separate from the stomach. Then, the midline fascial defect and skin were closed with interrupted 4-0 Vicryl suture with using Wire Twister for Neurosurgery.

2.3. Cell preparation

Mononuclear cells were isolated from the peripheral venous blood of patients on hydroxypropyl methylcellulose by centrifugation at 500×g for 20 min. White blood cells were isolated from the peripheral blood of mice by using erythrocyte lysate (BD Biosciences, USA). Mononuclear cells were obtained from the mouse spleen and heart with a gentleMACS Dissociator.

MDSCs were also isolated from the mouse spleen by using a mouse MDSC isolation kit (Miltenyi Biotec, Germany) according to the manufacturer's instructions. Disrupt spleen in PBS containing 2% foetal bovine serum (FBS). Then, the cell suspension was filtered through a 70 μm mesh nylon strainer to removed aggregates and debris. After centrifugation (300 × g for 10 min), the cells were resuspended at 1 × 10⁸ nucleated cells/mL in medium. Add FcR blocker, isolation cocktai and RapidSpheres™ to the resuspended cells suspension in turn, mix and incubate for 5 min at room temperature. Subsequently, MDSCs were isolated through a magnet. FACS was used to evaluate the separation efficiency of MDSCs isolated from the spleen. We found that the isolation efficiency was approximately 59.4% (Supplementary Figure 1). At last, the isolated MDSCs were resuspend and cultured at 2 × 10⁵ nucleated cells/mL in recommended medium.

Figure 1. — The circulating MDSC ratio is correlated with A_2BAR mRNA expression in AMI patients. (A) Representative flow cytometry images of MDSCs in the circulation of patients. (B) Mean fluorescence intensity of CD11b⁺ CD14^– cells. (C) Expression of A_2BAR mRNA in the PBMCs of AMI patients. (D) Correlation of the circulating MDSC ratio and A_2BAR mRNA expression in the mononuclear cells of AMI patients. For each group: n = 10, three independent experiments. Statistical analysis was performed using Student’s t test (B, C) or Pearson’s analysis (D). *p < 0.001 vs. the control group.

2.4. FACS analysis

Isolated cells were fixed in 1% paraformaldehyde (Sigma-Aldrich, USA) and incubated with PE-conjugated antihuman CD14, FITC-conjugated antihuman CD11b, PE-conjugated antimouse CD11b, and FITC-conjugated antimouse Gr-1 antibodies for 1 h on ice. After washing three times with 1% BSA in PBS, the cells were analysed with a FACScan flow cytometer to detect human MDSCs (CD11b⁺ CD14^–) and mouse MDSCs (CD11b⁺ Gr-1⁺). All antibodies and the FACScan flow cytometer were purchased from BD Biosciences.

2.5. Immunofluorescence staining

Twenty-four hours later, the mice were sacrificed by intraperitoneal injection of sodium pentobarbital (130 mg/kg). Heart tissue specimens were harvested and prepared for immunofluorescence staining [15]. Heart tissue was fixed in 10% formaldehyde (Sigma-Aldrich, USA) and then embedded in paraffin. The tissue sections (2 μm thick) were incubated with PE-conjugated antimouse CD11b and FITC-conjugated antimouse Gr-1 antibodies and then with DAPI (1 μm/ml) (Roche) in the dark for 15 min. Finally, mouse MDSCs (CD11b⁺ Gr-1⁺) were detected by inverted phase contrast fluorescence microscopy (Olympus, Japan).

2.6. A2bar mRNA expression

Total RNA was isolated from mononuclear cells using the TRIzol method according to the manufacturer’s protocol. The concentration and purity of RNA were assessed by determining the relative absorbance ratio at 260/280 with a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). cDNA was synthesised using a PrimeScript^TM RT reagent kit (TAKARA, Japan) with gDNA Eraser. A_2BAR (sense: 5′-CTCCATCTTCAGCCTTCT-3′; anti-sense: 5′-ACCAAACTTTTATACCTGAGC-3′) and GAPDH (sense: 5′-GGTGAAGGTCGGAGTCAACGGATTTGGTCG-3′; antisense: 5′-GGATCTCGCTCCTGGAAGATGGTGATGGG-3′) primers were used. A_2BAR expression was normalised to GAPDH expression and calculated by the 2^−ΔΔCt method.

2.7. Histopathology and immunohistochemical staining

Hematoxylin–eosin (HE) staining was performed to evaluate heart tissue damage. Paraffin heart tissue sections were stained with HE by using a HE staining kit (Beyotime, China) according to the manufacturer’s protocol. Morphological changes in myocardial tissue were assessed using an optical microscope. Cardiac muscle structure, myocardial cell fibrils swelling and arrangement, and granulocytes infiltration in heart specimens were observed and measured [33]. A semiquantitative score was obtained to assess the degree of myocardial injury.

Tetrazolium chloride (TTC) staining was performed to detect the area of myocardial infarction [34]. Following MI, myocardial tissues were rapidly removed and sliced into 2 mm sections. Then, the sections were incubated TTC solution (Sigma, USA) at 37 °C for 30 min. Infarct areas (white) in the myocardial tissues were photographed and measured by Image J software. The ratio of the infarct area to the corresponding cardiac cross-sectional area was calculated and compared the differences among groups.

Immunohistochemical staining was performed to detect the nuclei of apoptotic myocardial cells by using a TUNEL staining kit (Beyotime, China) according to the manufacturer’s protocol. The number of apoptotic cells with TUNEL-positive nuclei was counted.

2.8. Echocardiography

Twenty-four hours after MI model establishment, the cardiac systolic function of the mice was evaluated by transthoracic echocardiography. The ejection fraction (EF), left ventricular shortening (LVFS), left ventricular end diastolic diameter (LVIDd), and left ventricular systolic inner diameter (LVIDs) were calculated.

2.9. Statistical analysis

Statistical analyses were performed with GraphPad Prism version 9.0. All continuous variables are expressed as the mean ± SD. Student’s t test (2 groups) or one-way ANOVA (≥3 groups) was used to assess differences among groups. Pearson correlation analysis was used to assess the correlation between the circulating MDSC ratio and A_2BAR mRNA expression. p < 0.05 was considered statistically significant.

3. Results

3.1. The circulating MDSC ratio is correlated with A_2BAR mRNA expression in AMI patients

The circulating MDSC ratio was significantly increased in AMI patients compared to controls (Figure 1(A,B)). We further assessed A_2BAR mRNA expression in mononuclear cells by qRT-PCR. The results showed that A_2BAR mRNA expression was also increased in AMI patients compared to controls (Figure 1(C)). Pearson correlation analysis showed that the circulating MDSC ratio was positively correlated with A_2BAR mRNA expression (r = 0.86, p < 0.001; Figure 1(D)).

3.2. A_2BAR regulated MDSCs mobilisation after AMI

To explore whether A_2BAR regulates the mobilisation of MDSCs after AMI, the A_2BAR antagonist MRS1784 (1 mg/kg) (Selleck, USA) was injected intraperitoneally into mice before LADCA ligation (Figure 2(A)). We found that 24 h after LADCA ligation, the MDSCs ratios in the circulation (Figure 2(B,C)) and infarcted heart (Figure 2(B,D)) were significantly increased in the AMI group compared to the control and sham group.

Figure 2. — A_2BAR regulated the mobilisation of MDSCs after AMI. (A) The different groups of mice. Male C57BL6 mice (age: 8–10 weeks, weight: 20–22 g) were randomly divided into 4 groups. The control group (n = 5) did not undergo any operation. The sham group (n = 5) underwent sham operation without coronary artery ligation. The AMI group (n = 10) underwent LADCA ligation. The A_2BAR blockade group (n = 10) received intraperitoneal injection of the A_2BAR antagonist MRS1784 (1 mg/kg) before LADCA ligation. (B) Representative flow cytometry images of MDSCs in the circulation, infarcted heart, and spleen among the 4 groups. (C) Mean fluorescence intensity of CD11b⁺ CD14^– cells in the circulation of mice. (D) Mean fluorescence intensity of CD11b cells in the infarcted mouse heart. (E) Mean fluorescence intensity of CD11b⁺ CD14^–cells in the mouse spleen. (F) Representative immunofluorescence staining images of CD11b (red), Gr-1 (green), and DAPI (blue) staining in the infarcted mouse heart and merged images (right column). For each group: n = 5 (A–E), n = 3 (F); three independent experiments. Statistical analysis was performed using one-way ANOVA. *p < 0.001 vs. the control and sham groups; *p < 0.001 vs. the AMI group.

However, the ratio of MDSCs in the spleen was significantly decreased in the group that underwent LADCA ligation compared to the control and sham groups (Figure 2(B,E)). A_2BAR blockade significantly decreased the MDSC ratio in the circulation (Figure 2(B,C)) and in infarcted heart (Figure 2(B,D)) after LADCA ligation. However, the decrease in the MDSC ratio in the mouse spleen was significantly prevented by A_2BAR blockade (Figure 2(B,D)).

Immunofluorescence revealed that the MDSC ratio was increased in the infarcted mouse heart and that this increase was abolished by A_2BAR blockade (Figure 2(F), Supplementary Figure 2). All of the data suggested that A_2BAR blockade effectively prevents the reduction in the MDSC ratio in the spleen and decreases the MDSC ratio in the circulation and infarcted heart.

3.3. A_2BAR blockade alleviated myocardial injury after AMI

The effect of A_2BAR blockade on histopathological changes in the mouse heart after LADCA ligation was examined by HE staining. The results showed that 24 h after LADCA ligation, the infarcted cardiac muscle exhibited a large number of inflammatory granulocytes infiltration, fibrous structure disorder, myocardial fibre swelling and rupture (Figure 3(A,B), Supplementary Figure 3). While A_2BAR blockade alleviated myocardial injury after LADCA ligation. Similar results were found in TTC staining which showed that A_2BAR blockade can significantly alleviate the area of myocardial infarction in AMI mice (Supplementary Figure 3).

Further TUNEL staining showed that A_2BAR blockade significantly reduced cardiac myocyte apoptosis after AMI (Figure 3(C,D)). Moreover, we found that mice with AMI exhibited decreased cardiac systolic function (Figure 3(E,F), Supplementary Table 2) and that A_2BAR blockade improved cardiac systolic function after MI.

These results suggested that A_2BAR blockade effectively alleviates myocardial injury and improves cardiac systolic function after AMI.

3.4. Spleen-derived MDSC mobilisation after AMI

To explore whether the mobilised MDSCs in mice with AMI are derived from the spleen, splenectomy was performed before LADCA ligation (Figure 4(A)). We found that similar to A_2BAR blockade, splenectomy significantly decreased the MDSC ratio in the circulation (Figure 4(B,C)). The MDSC ratio in the infarcted heart was significantly decreased after splenectomy, similar to after A_2BAR blockade (Figure 4(B,C)).

To further verify that spleen-derived MDSC mobilisation led to myocardial injury after AMI, spleen-derived MDSCs (2 × 10⁵/ml) were isolated and injected into mice that underwent splenectomy via the medial canthus vein before LADCA ligation (Figure 4(A)). We found that compared to A_2BAR blockade and splenectomy, MDSC injection significantly increased the MDSC ratio in the circulation (Figure 4(B,D)). The MDSC ratio in the infarcted heart was significantly increased after MDSC injection compared to after A_2BAR blockade and splenectomy (Figure 4(B,D)).

Immunofluorescence also revealed that both A_2BAR blockade and splenectomy decreased the MDSC ratio and that MDSC injection increased the ratio of MDSCs in the infarcted hearts of mice with AMI (Figure 4(E), Supplementary Figure 1). These results suggested that the spleen is the source of mobilised MDSCs in mice with AMI.

3.5. Spleen-derived MDSC mobilisation led to myocardial injury after AMI

We examined whether splenectomy affects myocardial injury and function in mice with AMI. We found that similar to A_2BAR blockade, splenectomy alleviated myocardial injury (Figure 4(F,G), Supplementary Figure 3) and decreased the number of apoptotic cells (Figure 4(H,I)) in the infarcted hearts of mice with AMI. Cardiac ultrasound also showed that splenectomy had the same effect in preserving cardiac systolic function after AMI (Figure 4(J,K)).

Further study showed that compared to A_2BAR blockade and splenectomy, MDSC injection aggravated myocardial injury (Figure 4(F,G), Supplementary Figure 3), increased the number of apoptotic cells (Figure 4(H,I)), and decreased cardiac systolic function (Figure 4(J,K)). These results suggested that spleen-derived MDSC mobilisation is the main cause of myocardial injury after AMI.

4. Discussion

In the present study, we revealed that spleen-derived MDSCs mobilise into the circulation and infarcted heart tissue, leading to myocardial cell apoptosis and tissue inflammatory damage and ultimately impairing cardiac systolic function. A_2BAR blockade can inhibit myocardial cell apoptosis, alleviate myocardial inflammatory injury, and improve myocardial systolic function, mainly via prevention of spleen-derived MDSC mobilisation after AMI.

AMI is an acute fatal disease characterised by massive immune cell infiltration into the myocardium following ischaemia and reperfusion [35]. Exploring the characteristics of the immune cells infiltrating the myocardium and identifying relevant interventions can help prevent irreversible myocardial injury after MI. In this study, we first revealed that blocking A_2BAR prevented spleen-derived MDSC mobilisation, alleviated myocardial injury, and improved the cardiac systolic function of mice subjected to LADCA ligation. This suggests that preventing the mobilisation of spleen-derived MDSCs is a potential strategy for AMI treatment.

MDSCs, including immature granulocytes, macrophages, and dendritic cells at different stages of differentiation, are well-known immunosuppressive cells that play a decisive role in many disease states [7]. A widely accepted viewpoint is that infiltrating MDSCs can secrete high levels of inflammatory cytokines to mediate uncontrolled inflammation and accelerate inflammatory damage to tissues and organs [36,37]. Recent studies have reported that MDSCs are mobilised and recruited to the infarcted myocardium in the acute stage of AMI, acting as primary infiltrating myeloid cells and contributing directly to the oxidative burst, secretion of proteolytic enzymes, and promotion of cardiomyocyte death [9,16,17]. Consistent with these previous studies, our study observed that the content of MDSCs was significantly increased in the circulation of AMI patients. This phenomenon was also observed in the mice subjected to LADCA ligation. Furthermore, our study also revealed that enhanced infiltration of MDSCs in the infarcted heart was associated with myocardial cell apoptosis and tissue inflammatory damage in mice subjected to LADCA ligation. In addition, we observed that the content of MDSCs was significantly decreased in the spleens of mice subjected to LADCA ligation. This result indicates that the spleen is a potential source of MDSCs during AMI.

The spleen is an easily accessible peripheral immune organ and is thought to be the source of large quantities of immunocytes, including MDSCs, lymphocytes and macrophages [38,39]. Various studies have indicated that spleen-derived CD11b⁺ Gr-1⁺ cells are the major contributors to inflammatory reactions and organ damage [15,16,40]. In this study, we found that splenectomy significantly decreased the MDSC ratio in the circulation and infarcted myocardium. These results further confirm that the spleen is the source of MDSCs during AMI. Interestingly, myocardial damage was mild in mice subjected to splenectomy before AMI. Considering that there are numerous immune-related cells in the spleen, spleen-derived MDSCs were isolated and injected intravenously into mice before LADCA ligation. The results showed that intravenous administration of MDSCs aggravated myocardial injury in mice subjected to LADCA ligation by inducing infiltration of MDSCs into the infarcted myocardium. All of these results demonstrate that spleen-derived MDSC mobilisation is an important cause of myocardial damage during AMI. Therefore, investigating the mechanism of spleen-derived MDSC mobilisation during AMI may provide a scientific basis for AMI treatment.

A_2BAR is a G-protein coupled adenosine receptor that is widely expressed in haematopoietic cells and plays an important role in many pathophysiologic conditions [41–43]. A_2BAR is expressed in Gr1⁺ cells, and evidence has revealed that A_2BAR promotes the accumulation of intratumoral CD11b⁺ Gr1⁺ cells in many tumour models and that pharmacological blockade of A_2BAR significantly reduces tumour growth [25,29

]. Some biomolecules and synthetic drugs protect organs, including the heart, liver, and brain, against ischaemic–reperfusion injury via A_2BAR signalling [44–47].

In this study, we found that A_2BAR mRNA was highly expressed in the mononuclear cells of AMI patients. This result indicates that A_2BAR may be involved in MDSC mobilisation during AMI. To further explore this issue, MRS-1754, a selective A_2BAR antagonist [48,49], was intraperitoneally injected into mice before LADCA ligation. We found that blocking A_2BAR with MRS-1754 prevented spleen-derived MDSC mobilisation and improved the cardiac systolic function of mice with LADCA ligation.

5. Conclusion

In our study, we first revealed that A_2BAR plays a pivotal role in myocardial injury by facilitating spleen-derived MDSC mobilisation during the acute phase of AMI. Blocking A_2BAR with MRS-1754 improves cardiac systolic function. This effect is, at least in part, dependent on impaired spleen-derived MDSC mobilisation. Therefore, our study suggested that A_2BAR-mediated spleen-derived MDSC mobilisation is a potential therapeutic target for AMI.

6. Limitations

There are two major limitations to this study. First, we did not explore the role of MDSC subtypes in AMI. Changes in the A_2BAR signalling pathway in MDSCs need to be further studied. Furthermore, we only explored the mechanism of MDSC mobilisation within 24 h after AMI. Third, small number of patients were included in this study. It may affect the credibility of the results. Therefore, we would conduct a larger sample size study to verify the results. Therefore, the mechanism of MDSC mobilisation during the recovery period after AMI needs to be further explored.

Supplementary Material

Supplemental Material

IANN_A_2084153_SM2883.zip^{(2.3MB, zip)}

Acknowledgments

The authors thank Dr. Xiaolong Zhu (Department of Central Lab, Yi Ji Shan hospital Affiliated to Wannan Medical College) and Dr. Lianjun Hen (Precision Medicine Center, Yi Ji Shan hospital Affiliated to Wannan Medical College) for their kindly supports in FACS analysis.

Funding Statement

The article “The mobilization of splenic reservoir myeloid-derived suppressor cells in sepsis-induced myocardial injury” indicated that splenic reservoir CD11b⁺Gr-1⁺ cells rapidly migrated into circulation and the heart, further impairing heart function via the high expression of P53 through the inhibition of mTOR in sepsis. However, this study showed that blocking of A_2BAR alleviates myocardial damage and improve myocardial systolic function through inhibiting spleen-derived MDSCs mobilisation after acute myocardial infarction. These two articles focussed on the role of MDSC in different disease models, and the content is not repeated. The author Cong Fu and Yuhan Cao participated the two experiments and both the two experiments were funded by the Natural Science Foundation of China (81700265 to Cong Fu and 81702092 to Yuhan Cao), and the Key Medical and Health Specialty Construction project of Anhui (KZSJZ008).

Ethical statement

This study had been approved by the Ethics Committee on scientific research and new technology of Yi Ji Shan Hospital affiliated to Wan Nan Medical College (NO. (2021)LSGY(31)). All participants agreed to participate in the study. Written informed consents were obtained from all subjects for the use of their blood samples for research purposes. Studies involving human participants are subject to the Declaration of Helsinki. The animal experimental protocol of this study had been approved by the Experimental animal welfare and ethics committee of Wannan Medical College (NO. LLSC-2021-091). Studies involving animals comply with the ARRIVE guidelines.

Disclosure statement

The authors report no relationships that could be construed as a conflict of interest.

Data availability statement

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Author contributions

Study concept and design: Zongyin Yu, Shengxing Tang and Cong Fu. Clinical specimen collection: Yang Ling. Mice model and experiment operation: Zongyin Yu, Yang Ling and Qiancheng Xu. Data analysis and image processing: Zongyin Yu and Yuhan Cao. Drafting the manuscript: Zongyin Yu. Results interpretation and article revision: Zongyin Yu and Cong Fu. Supervision: Shengxing Tang.

References

1.Reed GW, Rossi JE, Cannon CP.. Acute myocardial infarction. Lancet. 2017;389(10065):1616–210. [DOI] [PubMed] [Google Scholar]
2.Jaffe AS, Apple FS.. The third universal definition of myocardial infarction-moving forward. Clin Chem. 2012;58(12):1727–1738. [DOI] [PubMed] [Google Scholar]
3.Anderson JL, Morrow DA.. Acute myocardial infarction. N Engl J Med. 2017;376(21):2053–2064. [DOI] [PubMed] [Google Scholar]
4.Niccoli G, Montone RA, Sabato V, et al. Role of allergic inflammatory cells in coronary artery disease. Circulation. 2018;138(16):1736–1748. [DOI] [PubMed] [Google Scholar]
5.Li Y, Zhang Y, Lu J, et al. Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. J Cell Mol Med. 2021;25(17):8087–8094. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Kuan R, Agrawal DK, Thankam FG.. Treg cells in atherosclerosis. Mol Biol Rep. 2021;48(5):4897–4910. [DOI] [PubMed] [Google Scholar]
7.Veglia F, Perego M, Gabrilovich D.. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Gabrilovich DI, Nagaraj S.. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Ge Y, Cheng D, Jia Q, et al. Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: good or bad. Immune Netw. 2021;21(3):e21. [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Gabrilovich DI, Ostrand-Rosenberg S, Bronte V.. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Hosomi S, Koyama Y, Watabe T, et al. Myeloid-derived suppressor cells infiltrate the brain and suppress neuroinflammation in a mouse model of focal traumatic brain injury. Neuroscience. 2019;406:457–466. [DOI] [PubMed] [Google Scholar]
12.Young MR, Newby M, Wepsic HT.. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 1987;47(1):100–105. [PubMed] [Google Scholar]
13.Sun SN, Ni SH, Li Y, et al. G-MDSCs promote aging-related cardiac fibrosis by activating myofibroblasts and preventing senescence. Cell Death Dis. 2021;12(6):594–609. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Muller I, Janson L, Sauter M, et al. Myeloid-derived suppressor cells restrain natural killer cell activity in acute coxsackievirus B3-induced myocarditis. Viruses. 2021;13(5):889–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Fu C, Xu Q, Tang S, et al. The mobilization of splenic reservoir myeloid-derived suppressor cells in sepsis-induced myocardial injury. Am J Transl Res. 2020;12(11):7114–7126. [PMC free article] [PubMed] [Google Scholar]
16.Yao T, Lu W, Zhu J, et al. Role of CD11b + Gr-1+ myeloid cells in AGEs-induced myocardial injury in a mice model of acute myocardial infarction. Int J Clin Exp Path. 2015;8(3):3238–3249. [PMC free article] [PubMed] [Google Scholar]
17.Wenbing L, Yicheng J, Xiaoxia C, et al. Mobilization and pathological effect of MDSCs in acute coronary syndrome. J Southeast Univ (Med Sci Ed.). 2012;31(3):254–260. [Google Scholar]
18.Sun Y, Huang P.. Adenosine A2B receptor: from cell biology to human diseases. Front Chem. 2016;4(37):37–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Patel L, Thaker A.. The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy. J Pharmacol Pharmacother. 2015;6(3):147–153. [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Merighi S, Simioni C, Gessi S, et al. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia. 2009;11(10):1064–1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Yi Y, Shen Y, Wu Q, et al. Protective effects of oxymatrine on vascular endothelial cells from high-glucose-induced cytotoxicity by inhibiting the expression of A2B receptor. Cell Physiol Biochem. 2018;45(2):558–571. [DOI] [PubMed] [Google Scholar]
22.Tofovic SP, Salah EM, Smits GJ, et al. Dual A1/A2B receptor blockade improves cardiac and renal outcomes in a rat model of heart failure with preserved ejection fraction. J Pharmacol Exp Ther. 2016;356(2):333–340. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Zhang H, Zhong H, Everett T, et al. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm. 2014;11(1):101–109. [DOI] [PubMed] [Google Scholar]
24.Toldo S, Zhong H, Mezzaroma E, et al. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012;343(3):587–595. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Sorrentino C, Miele L, Porta A, et al. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget. 2016;7(39):64274–64288. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Sorrentino C, Miele L, Porta A, et al. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget. 2015;6(29):27478–27489. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Morello S, Miele L.. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. Oncoimmunology. 2014;3:e27989. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Iannone R, Miele L, Maiolino P, et al. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 2013;15(12):1400–1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Ryzhov S, Novitskiy SV, Goldstein AE, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b + Gr1+ cells. J Immunol. 2011;187(11):6120–6129. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Wu Y, Zhang M, Lu K, et al. Adenosine A2b receptor activation attenuates lung injury induced by renal ischemia–reperfusion in mice. Basic Clin Med. 2019;39(08):1102–1107. [Google Scholar]
31.Abarbanell AM, Herrmann JL, Weil BR, et al. Animal models of myocardial and vascular injury. J Surg Res. 2010;162(2):239–249. [DOI] [PubMed] [Google Scholar]
32.Li SC, Rangel AD, Kabeer MH.. Precision technique for splenectomy limits mouse stress responses for accurate and realistic measurements for investigating inflammation and immunity. Bio-protocol. 2019;9(15):1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Cheng B, Zhong JP, Wu FX, et al. Ebselen protects rat hearts against myocardial ischemia–reperfusion injury. Exp Ther Med. 2019;17(2):1412–1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Wu Z, Yu L, Li X, et al. Protective mechanism of trimetazidine in myocardial cells in myocardial infarction rats through ERK signaling pathway. Biomed Res Int. 2021;2021:1–8. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
35.Andreadou I, Cabrera-Fuentes HA, Devaux Y, et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res. 2019;115(7):1117–1130. [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263–309. [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Sendo S, Saegusa J, Morinobu A.. Myeloid-derived suppressor cells in non-neoplastic inflamed organs. Inflamm Regen. 2018;38(19):19–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Cole KE, Ly QP, Hollingsworth MA, et al. Human splenic myeloid derived suppressor cells: phenotypic and clustering analysis. Cell Immunol. 2021;363:104317–104328. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Bellomo A, Gentek R, Golub R, et al. Macrophage–fibroblast circuits in the spleen. Immunol Rev. 2021;302(1):104–125. [DOI] [PubMed] [Google Scholar]
40.Lu Y, Fu C, Xia C, et al. A method for separation and purification of mouse splenocytes by density gradient centrifugation. Prep Biochem Biotechnol. 2021;51(5):415–421. [DOI] [PubMed] [Google Scholar]
41.Gao ZG, Jacobson KA.. A2B adenosine receptor and cancer. IJMS. 2019;20(20):5139–5113. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Pasquini S, Contri C, Borea PA, et al. Adenosine and inflammation: here, there and everywhere. IJMS. 2021;22(14):7685–7614. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Franco R, Cordomí A, Llinas Del Torrent C, et al. Structure and function of adenosine receptor heteromers. Cell Mol Life Sci. 2021;78(8):3957–3968. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Hesse J, Groterath W, Owenier C, et al. Normoxic induction of HIF-1alpha by adenosine-A2B R signaling in epicardial stromal cells formed after myocardial infarction. FASEB J. 2021;35(5):e21517. [DOI] [PubMed] [Google Scholar]
45.Li J, Conrad C, Mills TW, et al. PMN-derived netrin-1 attenuates cardiac ischemia-reperfusion injury via myeloid ADORA2B signaling. J Exp Med. 2021; 218(6):1-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Zhang X, Du P, Luo K, et al. Hypoxia-inducible factor-1alpha protects the liver against ischemia-reperfusion injury by regulating the A2B adenosine receptor. Bioengineered. 2021;12(1):3737–3752. [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Dettori I, Gaviano L, Ugolini F, et al. Protective effect of adenosine A2B receptor agonist, BAY60-6583, against transient focal brain ischemia in rat. Front Pharmacol. 2020;11588757-588771. [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Ji X. Kim YC, Ahern DG, et al. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol. 2001; 61(6): 657-663. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material

IANN_A_2084153_SM2883.zip^{(2.3MB, zip)}

Data Availability Statement

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

[CIT0001] 1.Reed GW, Rossi JE, Cannon CP.. Acute myocardial infarction. Lancet. 2017;389(10065):1616–210. [DOI] [PubMed] [Google Scholar]

[CIT0002] 2.Jaffe AS, Apple FS.. The third universal definition of myocardial infarction-moving forward. Clin Chem. 2012;58(12):1727–1738. [DOI] [PubMed] [Google Scholar]

[CIT0003] 3.Anderson JL, Morrow DA.. Acute myocardial infarction. N Engl J Med. 2017;376(21):2053–2064. [DOI] [PubMed] [Google Scholar]

[CIT0004] 4.Niccoli G, Montone RA, Sabato V, et al. Role of allergic inflammatory cells in coronary artery disease. Circulation. 2018;138(16):1736–1748. [DOI] [PubMed] [Google Scholar]

[CIT0005] 5.Li Y, Zhang Y, Lu J, et al. Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. J Cell Mol Med. 2021;25(17):8087–8094. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0006] 6.Kuan R, Agrawal DK, Thankam FG.. Treg cells in atherosclerosis. Mol Biol Rep. 2021;48(5):4897–4910. [DOI] [PubMed] [Google Scholar]

[CIT0007] 7.Veglia F, Perego M, Gabrilovich D.. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0008] 8.Gabrilovich DI, Nagaraj S.. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0009] 9.Ge Y, Cheng D, Jia Q, et al. Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: good or bad. Immune Netw. 2021;21(3):e21. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0010] 10.Gabrilovich DI, Ostrand-Rosenberg S, Bronte V.. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0011] 11.Hosomi S, Koyama Y, Watabe T, et al. Myeloid-derived suppressor cells infiltrate the brain and suppress neuroinflammation in a mouse model of focal traumatic brain injury. Neuroscience. 2019;406:457–466. [DOI] [PubMed] [Google Scholar]

[CIT0012] 12.Young MR, Newby M, Wepsic HT.. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 1987;47(1):100–105. [PubMed] [Google Scholar]

[CIT0013] 13.Sun SN, Ni SH, Li Y, et al. G-MDSCs promote aging-related cardiac fibrosis by activating myofibroblasts and preventing senescence. Cell Death Dis. 2021;12(6):594–609. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0014] 14.Muller I, Janson L, Sauter M, et al. Myeloid-derived suppressor cells restrain natural killer cell activity in acute coxsackievirus B3-induced myocarditis. Viruses. 2021;13(5):889–903. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0015] 15.Fu C, Xu Q, Tang S, et al. The mobilization of splenic reservoir myeloid-derived suppressor cells in sepsis-induced myocardial injury. Am J Transl Res. 2020;12(11):7114–7126. [PMC free article] [PubMed] [Google Scholar]

[CIT0016] 16.Yao T, Lu W, Zhu J, et al. Role of CD11b + Gr-1+ myeloid cells in AGEs-induced myocardial injury in a mice model of acute myocardial infarction. Int J Clin Exp Path. 2015;8(3):3238–3249. [PMC free article] [PubMed] [Google Scholar]

[CIT0017] 17.Wenbing L, Yicheng J, Xiaoxia C, et al. Mobilization and pathological effect of MDSCs in acute coronary syndrome. J Southeast Univ (Med Sci Ed.). 2012;31(3):254–260. [Google Scholar]

[CIT0018] 18.Sun Y, Huang P.. Adenosine A2B receptor: from cell biology to human diseases. Front Chem. 2016;4(37):37–11. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0019] 19.Patel L, Thaker A.. The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy. J Pharmacol Pharmacother. 2015;6(3):147–153. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0020] 20.Merighi S, Simioni C, Gessi S, et al. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia. 2009;11(10):1064–1073. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0021] 21.Yi Y, Shen Y, Wu Q, et al. Protective effects of oxymatrine on vascular endothelial cells from high-glucose-induced cytotoxicity by inhibiting the expression of A2B receptor. Cell Physiol Biochem. 2018;45(2):558–571. [DOI] [PubMed] [Google Scholar]

[CIT0022] 22.Tofovic SP, Salah EM, Smits GJ, et al. Dual A1/A2B receptor blockade improves cardiac and renal outcomes in a rat model of heart failure with preserved ejection fraction. J Pharmacol Exp Ther. 2016;356(2):333–340. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0023] 23.Zhang H, Zhong H, Everett T, et al. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm. 2014;11(1):101–109. [DOI] [PubMed] [Google Scholar]

[CIT0024] 24.Toldo S, Zhong H, Mezzaroma E, et al. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012;343(3):587–595. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0025] 25.Sorrentino C, Miele L, Porta A, et al. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget. 2016;7(39):64274–64288. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0026] 26.Sorrentino C, Miele L, Porta A, et al. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget. 2015;6(29):27478–27489. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0027] 27.Morello S, Miele L.. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. Oncoimmunology. 2014;3:e27989. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0028] 28.Iannone R, Miele L, Maiolino P, et al. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 2013;15(12):1400–1409. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0029] 29.Ryzhov S, Novitskiy SV, Goldstein AE, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b + Gr1+ cells. J Immunol. 2011;187(11):6120–6129. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0030] 30.Wu Y, Zhang M, Lu K, et al. Adenosine A2b receptor activation attenuates lung injury induced by renal ischemia–reperfusion in mice. Basic Clin Med. 2019;39(08):1102–1107. [Google Scholar]

[CIT0031] 31.Abarbanell AM, Herrmann JL, Weil BR, et al. Animal models of myocardial and vascular injury. J Surg Res. 2010;162(2):239–249. [DOI] [PubMed] [Google Scholar]

[CIT0032] 32.Li SC, Rangel AD, Kabeer MH.. Precision technique for splenectomy limits mouse stress responses for accurate and realistic measurements for investigating inflammation and immunity. Bio-protocol. 2019;9(15):1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0033] 33.Cheng B, Zhong JP, Wu FX, et al. Ebselen protects rat hearts against myocardial ischemia–reperfusion injury. Exp Ther Med. 2019;17(2):1412–1419. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0034] 34.Wu Z, Yu L, Li X, et al. Protective mechanism of trimetazidine in myocardial cells in myocardial infarction rats through ERK signaling pathway. Biomed Res Int. 2021;2021:1–8. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

[CIT0035] 35.Andreadou I, Cabrera-Fuentes HA, Devaux Y, et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res. 2019;115(7):1117–1130. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0036] 36.Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263–309. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0037] 37.Sendo S, Saegusa J, Morinobu A.. Myeloid-derived suppressor cells in non-neoplastic inflamed organs. Inflamm Regen. 2018;38(19):19–11. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0038] 38.Cole KE, Ly QP, Hollingsworth MA, et al. Human splenic myeloid derived suppressor cells: phenotypic and clustering analysis. Cell Immunol. 2021;363:104317–104328. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0039] 39.Bellomo A, Gentek R, Golub R, et al. Macrophage–fibroblast circuits in the spleen. Immunol Rev. 2021;302(1):104–125. [DOI] [PubMed] [Google Scholar]

[CIT0040] 40.Lu Y, Fu C, Xia C, et al. A method for separation and purification of mouse splenocytes by density gradient centrifugation. Prep Biochem Biotechnol. 2021;51(5):415–421. [DOI] [PubMed] [Google Scholar]

[CIT0041] 41.Gao ZG, Jacobson KA.. A2B adenosine receptor and cancer. IJMS. 2019;20(20):5139–5113. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0042] 42.Pasquini S, Contri C, Borea PA, et al. Adenosine and inflammation: here, there and everywhere. IJMS. 2021;22(14):7685–7614. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0043] 43.Franco R, Cordomí A, Llinas Del Torrent C, et al. Structure and function of adenosine receptor heteromers. Cell Mol Life Sci. 2021;78(8):3957–3968. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0044] 44.Hesse J, Groterath W, Owenier C, et al. Normoxic induction of HIF-1alpha by adenosine-A2B R signaling in epicardial stromal cells formed after myocardial infarction. FASEB J. 2021;35(5):e21517. [DOI] [PubMed] [Google Scholar]

[CIT0045] 45.Li J, Conrad C, Mills TW, et al. PMN-derived netrin-1 attenuates cardiac ischemia-reperfusion injury via myeloid ADORA2B signaling. J Exp Med. 2021; 218(6):1-11. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0046] 46.Zhang X, Du P, Luo K, et al. Hypoxia-inducible factor-1alpha protects the liver against ischemia-reperfusion injury by regulating the A2B adenosine receptor. Bioengineered. 2021;12(1):3737–3752. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0047] 47.Dettori I, Gaviano L, Ugolini F, et al. Protective effect of adenosine A2B receptor agonist, BAY60-6583, against transient focal brain ischemia in rat. Front Pharmacol. 2020;11588757-588771. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0048] 48.Ji X. Kim YC, Ahern DG, et al. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol. 2001; 61(6): 657-663. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Blocking the A2B adenosine receptor alleviates myocardial damage by inhibiting spleen-derived MDSC mobilisation after acute myocardial infarction

Zongying Yu

Yang Ling

Qiancheng Xu

Yuhan Cao

Shengxing Tang

Cong Fu